Výsledky vyhledávání - "N. STIELTJES"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Assessment of the impact of pharmaceutical consultations at initiation of a treatment with emicizumab in patients with severe hemophilia A without inhibitors]

Autor: M, Nasr Allah, R, Pieragostini, G, Oka, R, Batista, N, Stieltjes, I, Lopez

Publikováno v: Annales pharmaceutiques francaises. 80(6)

Since 2019, severe haemophilia A without inhibitors can be treated with emicizumab. Its action, route of administration and management justified the creation of new tools for therapeutic education sessions addressed to patients. The main objective of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::67105a55b8a89381b13297eb9ea3c400
https://pubmed.ncbi.nlm.nih.gov/35151626

Zobrazit plný text záznamu

Coût des facteurs antihémophiliques en hospitalisation

Autor: P. Paubel, V. Perut, N. Stieltjes, P. Randuineau, I. Lopez

Publikováno v: Annales Pharmaceutiques Françaises. 76:361-367

Resume Objectifs L’hemophilie est une maladie hemorragique rare. Elle se traduit cliniquement par des hemorragies spontanees ou provoquees. Les facteurs antihemophiliques constituent le principal traitement. Ce sont cependant des medicaments tres o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43d2c7985bcfd1bbc5ec4163497222c0
https://doi.org/10.1016/j.pharma.2018.03.006

Zobrazit plný text záznamu

Risques en dermatologie interventionnelle chez les patients hémophiles ou atteints de la maladie de Willebrand

Autor: Marie-Françoise Avril, M. Say, Nicolas Dupin, Johan Chanal, N. Stieltjes, Selim Aractingi

Publikováno v: Annales de Dermatologie et de Vénéréologie. 145:233-239

Resume Contexte La maladie de Willebrand (MW) et les hemophilies A (HA) et B (HB) representent la majorite des deficits constitutionnels en facteurs de la coagulation (DCFC). La nature et la frequence des complications qui peuvent survenir chez ces p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f2db05c098127cb4554505402f54ded
https://doi.org/10.1016/j.annder.2017.10.009

Zobrazit plný text záznamu

Post-authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study

Autor: C. Rothschild, S. Claeyssens, Y. Gruel, Thierry Lambert, Z. Tellier, M.-H. André, N. Stieltjes, Claude Negrier, Pierre Sié, Jeanne-Yvonne Borg, A. Bertrand, L. Sanhes

Publikováno v: Vox Sanguinis. 111:383-390

Background and Objectives A new fibrinogen concentrate Clottafact® was developed according to European guidelines on plasma-derived products. A post-authorization safety study was set up in 2009 as part of the risk management plan. This was a non-in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::771c794d743c5d92a1291c4a9e26a5e4
https://doi.org/10.1111/vox.12424

Zobrazit plný text záznamu

Plný text ve formátu HTML

Avulsions dentaires chez les patients sous clopidogrel : étude prospective bi-centrique

Autor: Christian Spaulding, Maria-Pia Gandolfini, Alp Alantar, Guy Princ, Yacine Sifi, Marc Baranes, Michel Hassin, N. Stieltjes

Publikováno v: Médecine Buccale Chirurgie Buccale. 22:173-183

Introduction : Le clopidogrel est un agent antiplaquettaire (AAP) indique dans la prevention de l’atherothrombose et des thromboses de stents coronaires. Il augmente le risque hemorragique lors des actes chirurgicaux. Son arret, meme transitoire, p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7c9946bc1d648592309b5d20fa64f858
https://doi.org/10.1051/mbcb/2016026

Zobrazit plný text záznamu

Postauthorization safety study of Clottafact ® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study

Autor: Vincent Piriou, Annie Borel-Derlon, A. Bertrand, J. Picard, Pierre Sié, Thierry Lambert, Y. Ozier, S. Claeyssens, E. de Maistre, Y. Gruel, M.-H. André, N. Stieltjes, Z. Tellier, A. Ducloy-Bouthors, François Fourrier, Claude Negrier, S. Boileau, Pascal Colson

Publikováno v: Vox Sanguinis
Vox Sanguinis, Wiley, 2018, 113 (2), pp.120-127. ⟨10.1111/vox.12624⟩

International audience; BACKGROUND AND OBJECTIVES:A postauthorization safety study was performed between 2009 and 2012 to describe the use of Clottafact® in acquired fibrinogen deficiency in real-life medical practice in France.MATERIALS AND METHODS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fb0104cdce5942b92e60d63e3a89a7f
https://hal.archives-ouvertes.fr/hal-01739807

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Cost of clotting factors in hospitalization]

Autor: P, Randuineau, N, Stieltjes, V, Perut, P, Paubel, I, Lopez

Publikováno v: Annales pharmaceutiques francaises. 76(5)

Hemophilia is a rare genetic disease, characterized by uncontrolled bleeding. Injections of clotting factor are the principal are the principal treatment. This drug is very expensive. The objectives of this study are to determine the cost of clotting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::405257ace2ab68a1e20c2ab2a273b897
https://pubmed.ncbi.nlm.nih.gov/29655485

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání